PAZENIR® (paclitaxel)

Drug PAZENIR® paclitaxel Pazenir Overview Pazenir is used to treat the following cancers in adults: metastatic breast cancer, when the first treatment has stopped working and standard treatment including an ‘anthracycline’ (another type of cancer medicine) is not suitable. ‘Metastatic’ means that the cancer has spread to other parts of the body; non-small cell lung […]

AVASTIN® (bevacizumab)

Drug AVASTIN® bevacizumab Avastin Overview This is a summary of the European public assessment report (EPAR) for Avastin. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Avastin. For practical information about using Avastin, […]

PERJETA® (pertuzumab)

Drug PERJETA® pertuzumab Perjeta Overview Perjeta is a cancer medicine for treating adults with ‘HER2-positive’ breast cancer (where a protein called HER2 is found on the cancer cells). Perjeta is used in the following situations: treatment of metastatic breast cancer (cancer that has spread to other parts of the body) that has not already been […]

LYNPARZA® (olaparib)

Drug LYNPARZA® olaparib Lynparza Overview Lynparza is a cancer medicine used on its own for: continuing treatment of high-grade (fast-growing) cancers of the ovaries, fallopian tubes (which connect the ovaries to the womb) and the peritoneum (membrane lining the abdomen) in: women whose cancer had come back (relapsed) after previous treatment and in whom platinum-based […]

IBRANCE® (palbociclib)

Drug IBRANCE® palbociclib Ibrance Overview This is a summary of the European public assessment report (EPAR) for Ibrance. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ibrance. For practical information about using Ibrance, […]

FASLODEX® (fulvestrant)

Drug FASLODEX® fulvestrant Faslodex Overview This is a summary of the European public assessment report (EPAR) for Faslodex. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Faslodex. For practical information about using Faslodex, […]

HALAVEN® (eribulin)

Drug HALAVEN® eribulin Halaven Overview This is a summary of the European public assessment report (EPAR) for Halaven. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Halaven. How is Halaven used? Halaven treatment should […]

CAELYX® (doxorubicin)

Drug CAELYX® doxorubicin  Caelyx Overview This is a summary of the European public assessment report (EPAR) for Caelyx. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Caelyx. How is Caelyx used? Caelyx should be […]

TAXOTERE® (docetaxel)

Drug TAXOTERE® Docetaxel Taxotere Overview Taxotere is a cancer medicine used to treat the following types of cancer: breast cancer. Taxotere can be used on its own after other treatments have failed. It can also be used with other cancer medicines (doxorubicin, cyclophosphamide, trastuzumab or capecitabine) in patients who have not yet received any treatment […]

TEPADINA® (thiotepa)

Drug TEPADINA® thiotepa Tepadina Overview This is a summary of the European Public Assessment Report (EPAR) for Tepadina. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tepadina. How […]